ISRCTN05585365已完成不适用
An Open-label, Randomized Study Comparing 3 Years Tamoxifen Versus 3 Years Letrozole as Continuation of Adjuvant Treatment of Postmenopausal Women with Estrogen Receptor (ER) Positive and/or Progesterone Receptor (PR) Positive Early Breast Cancer Who Already Completed 2 years Adjuvant Tamoxifen. A Large Thai Multicenter Study.
Thai Breast Cancer Study Group (Thailand)0 个研究点目标入组 1,000 人开始时间: 2005年10月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Patients with stage I, II or IIIa adenocarcinoma of the breast at diagnosis. Patients with breast cancer whose tumor has been completely removed macroscopically and margins of the resected tumor have been microscopically free of tumor. If appropriate, additional local (e.g. radiotherapy) and/or systemic (i.e. adjuvant chemotherapy) treatments are allowed.
- •2. Postmenopausal status defined by one of the following:
- •a. Age =55 years with cessation of menses
- •b. Age <55 but no spontaneous menses for at least 1 year
- •c. Age <55 and spontaneous menses within the past 1 year, but currently amenorrheic (e.g. spontaneous, or secondary to hysterectomy), and with postmenopausal gonadotrophin levels (luteinizing hormone and follicle stimulating hormone levels >40 IU/l) or postmenopausal estradiol levels (<5 ng/dl) or according to the definition of 'postmenopausal range' for the laboratory involved
- •d. Bilateral oophorectomy
- •3. Patients whose tumors are either ER+ and/or PR+ (defined as ER and/or PR =10 fmol/mg cytosol protein; or =10% of the tumor cells positive by immunohistochemical evaluation)
- •4. Under tamoxifen therapy for 2 years before randomization
- •5. At randomization, patients must have no clinical or radiological evidence of distant metastasis, and no other concomitant malignancy (confirmed by mammography, chest X-ray or computed tomography [CT] scan, bone scan and liver US)
- •6. Eastern Cooperative Oncology Group (ECOG) performance status of 0?2
- •7. No prior treatment with letrozole
- •8. Patients must be accessible for follow-up
- •9. Signed written informed consent
排除标准
- •1. Patients with any clinical or radiological evidence of distant spread of their disease at any point before randomization
- •2. Patients with other non-malignant systemic diseases including uncontrolled infections, uncontrolled type 2 diabetes mellitus, uncontrolled thyroid dysfunction, cardiovascular, renal, hepatic, and lung diseases which would prevent prolonged follow-up. Patients with previous history of thrombosis or thromboembolism can be included only if medically suitable. Patients with a known history of human immunodeficiency virus (HIV) are excluded.
- •3. Total serum calcium >2.75 mmol/l (11.0 mg/dl)
- •4. White Blood Cell Count (WBC) <3.0 x 10^9/l or granulocytes <1.5 x 10^9/l, platelets <100 x 10^9/l
- •5. Aspartate amino transferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and/or alanine amino transferase (ALT)/serum glutamic pyruvic transaminase (SGPT) >3 upper limit of normal (ULN) in combination with other laboratory and clinical abnormalities indicating liver insufficiency to a degree that precludes dosing with letrozole (Child-Pugh grade C)
- •6. Patients with abnormal renal function as defined by a serum creatinine =3 mg/dl (265.2 mmol/l)
- •7. Previous history of fracture within 2 years
- •8. Patients treated with other systemic investigational drug(s) and/or device(s) within the past 30 days
- •9. History of non-compliance to medical regimens and patients who are considered potentially unreliable
- •10. Mental illness that precludes the patient from giving informed consent
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in people who have not taken erythropoiesis-stimulating agents (ESA's) before and who require red blood cell transfusions.Myelodysplastic syndrome (MDS)MedDRA version: 20.0Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864EUCTR2017-003190-34-NLCelgene Corporation350
进行中（未招募）
1 期
A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in people who have not taken erythropoiesis-stimulating agents (ESA's) before and who require red blood cell transfusions.EUCTR2017-003190-34-GRCelgene Corporation350
进行中（未招募）
1 期
A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in people who have not taken erythropoiesis-stimulating agents (ESA's) before and who require red blood cell transfusions.Myelodysplastic syndrome (MDS)MedDRA version: 20.0Level: LLTClassification code: 10068361Term: MDS Class: 10029104CTIS2022-501485-22-00Celgene Corp.363
进行中（未招募）
1 期
A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in people who have not taken erythropoiesis-stimulating agents (ESA's) before and who require red blood cell transfusions.Myelodysplastic syndrome (MDS)MedDRA version: 20.0 Level: LLT Classification code 10068361 Term: MDS System Organ Class: 100000004864EUCTR2017-003190-34-ESCelgene Corporation350
进行中（未招募）
1 期
A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in people who have not taken erythropoiesis-stimulating agents (ESA's) before and who require red blood cell transfusions.Myelodysplastic syndrome (MDS)MedDRA version: 20.0Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864EUCTR2017-003190-34-DECelgene Corporation350